Assessing quality standards of biomarker measurement in first-trimester combined screening for preeclampsia in the Chinese population: A multicenter study.

Authors

Jiao Liu, Xiaotian Li, Huixia Yang, Qiongjie Zhou, Hao Ying, Rong Zhou, Yanping Zhang, Wang Xueyin, Han Xie, Xinzhi Tu, Lin Kong, Jie Qin, Chi Chiu Wang, Xiaohong Lu, Long Nguyen-Hoang, Daljit S Sahota, Liona C Poon

Published in

Acta obstetricia et gynecologica Scandinavica. Jul 14, 2026. Epub Jul 14, 2026.

Abstract

The first-trimester combined screening test for preterm preeclampsia (preterm-PE) has been implemented in Mainland China. This study aims, first, to evaluate the applicability of multiple of the median (MoM) models based on biomarkers developed and utilized in a European population for prospective preterm-PE screening in Mainland China; second, to assess the criteria for biomarker adjustment; and third, to establish criteria for continuous quality assurance in the screening process.
In this prospective multicenter cross-sectional study, 22 066 singleton pregnancies undergoing preterm-PE screening at 11 ^+ 0-13 ^+ 6 weeks were recruited from six tertiary hospitals in Mainland China. Mean arterial pressure (MAP) and placental growth factor (PlGF) were measured and converted to their equivalent MoM values using Fetal Medicine Foundation MoMing models incorporated in commercial software. PlGF levels were also determined using immunoassays developed in China. MoM and log₁₀MoM distributions in the initial screened subjects were assessed for (1) central tendency and dispersion and (2) whether biomarker MoM distributions needed to be recentered. Biomarker central tendency and temporal stability both before and after recentering were assessed using Cumulative Sum plots. Distribution central tendency was considered good if its median MoM was between 0.95 and 1.05 and acceptable if between 1.05 and 1.10.
After excluding the initial 400 pregnancies from each center, all PlGF, but not all MAP MoM distributions, required recentering. Post-recentering, the overall distribution median (95% confidence interval) MoM values for MAP and PlGF were 1.003 (1.001, 1.004) and 1.004 (0.996, 1.013), respectively.
Chinese centers performing combined PE screening should assess biomarker MoM distributions in their initial cases to ensure that they conform to the expected central tendencies assumed in the risk estimation models.

PMID:
42452901
Bibliographic data and abstract were imported from PubMed on 16 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.